Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial
Title:
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial
Author:
Robbins, Jonathan A. Tait, Dereck Huang, Qinlei Dubey, Sheri Crumley, Tami Cote, Josee Luk, Julie Sachs, Jeffrey R. Rutkowski, Kathryn Park, Harriet Schwab, Robert Howitt, William Joseph Rondon, Juan Carlos Hernandez-Illas, Martha O'Reilly, Terry Smith, William Simon, Jakub Hardalo, Cathy Zhao, Xuemei Wnek, Richard Cope, Alethea Lai, Eseng Annunziato, Paula Guris, Dalya Stoch, S. Aubrey
Appeared in:
EBioMedicine
Paging:
Volume 82 () nr. C pages p.
Year:
2022
Contents:
Publisher:
Merck Sharp & Dohme Corp., a subsidiary Merck & Co., Inc., The Author(s)